New patient-reported outcomes data shows improved function and reduced symptom burden with HERNEXEOS® (zongertinib tablets) as an initial treatment option in HER2 (ERBB2)-mutant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results